Bax inhibitor peptide P5
Discontinued ProductUnfortunately Bax inhibitor peptide P5 (Cat. No. 1786) has been withdrawn from sale for commercial reasons.
Sold under license
|Storage||Desiccate at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Preparing Stock Solutions
The following data is based on the product molecular weight 616.77. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.62 mL||8.11 mL||16.21 mL|
|5 mM||0.32 mL||1.62 mL||3.24 mL|
|10 mM||0.16 mL||0.81 mL||1.62 mL|
|50 mM||0.03 mL||0.16 mL||0.32 mL|
References are publications that support the products' biological activity.
Sawada et al (2003) Cytoprotective membrane-permeable peptides designed from the Bax-binding domain of Ku70. Nat.Cell.Biol. 5 352 PMID: 12652309
View Related Products by Product Action
Keywords: Bax inhibitor peptide P5, supplier, inhibitors, inhibits, Bax-mediated, apoptosis, Bcl-XL, Mcl-1, Bcl-2, Family, Bax, inhibitor, peptideP5, Bcl-2, Family, Bcl-2, Family, Tocris Bioscience
Citations for Bax inhibitor peptide P5
Citations are publications that use Tocris products.
Currently there are no citations for Bax inhibitor peptide P5.
Reviews for Bax inhibitor peptide P5
There are currently no reviews for this product. Be the first to review Bax inhibitor peptide P5 and earn rewards!
Have you used Bax inhibitor peptide P5?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.